Links to 5 New HCV Articles

[Guest guest]

A wild ride in Hepatitis C treatment: Vertex stock gives investors whiplash

Examiner.com

Traders have been consistently excited about the positive news from Vertex's

Hepatitis C virus (HCV) treatment telaprevir. And some news about a treatment

for cystic fibrosis pushed the stock to it's 52 week high on March 4. But

investors reacted (or ...

See all stories on this topic »

Inovio Pharmaceuticals' partner ChronTech Pharma begins phase 2 trial for ...

Proactive Investors USA & Canada

Vaccine developer Inovio Pharmaceuticals (AMEX: INO) said Monday that its

partner, ChronTech Pharma, has begun a phase IIb clinical trial for a hepatitis

C DNA vaccine delivered through Inovio's electroportation technology. Hepatitis

C is the most ...

See all stories on this topic »

: More Veterans May Be Exposed To Hepatitis, HIV

WHIO Dayton

DAYTON, Ohio -- Members of Congress went inside the VA Dental Clinic on Monday

morning where at least nine patients are suspected of contracting hepatitis.

Rep. Mike is investigating the VA after a now-retired dentist was found

using dirty tools ...

See all stories on this topic »

New Hepatitis C Data from Boehringer Ingelheim HCV Portfolio to Be Presented ...

Montreal Gazette

New data from the Boehringer Ingelheim hepatitis C virus (HCV) portfolio will be

presented in oral scientific sessions at the International Liver Congress TM

2011, the 46th Annual Meeting of the European Association for the Study of the

Liver (EASL), ...

See all stories on this topic »

Biolex to present final phase II B results of Hepatitis C drug Locteron at ...

pharmabiz.com

Biolex Therapeutics, Inc. announced that final results from its select-2 phase

II b trial of Locteron for the treatment of Hepatitis C has been accepted for

two presentations on March 31, 2011 at the 46th Annual Meeting of the European

Association for ...

See all stories on this topic »

[Guest guest]

A wild ride in Hepatitis C treatment: Vertex stock gives investors whiplash

Examiner.com

Traders have been consistently excited about the positive news from Vertex's

Hepatitis C virus (HCV) treatment telaprevir. And some news about a treatment

for cystic fibrosis pushed the stock to it's 52 week high on March 4. But

investors reacted (or ...

See all stories on this topic »

Inovio Pharmaceuticals' partner ChronTech Pharma begins phase 2 trial for ...

Proactive Investors USA & Canada

Vaccine developer Inovio Pharmaceuticals (AMEX: INO) said Monday that its

partner, ChronTech Pharma, has begun a phase IIb clinical trial for a hepatitis

C DNA vaccine delivered through Inovio's electroportation technology. Hepatitis

C is the most ...

See all stories on this topic »

: More Veterans May Be Exposed To Hepatitis, HIV

WHIO Dayton

DAYTON, Ohio -- Members of Congress went inside the VA Dental Clinic on Monday

morning where at least nine patients are suspected of contracting hepatitis.

Rep. Mike is investigating the VA after a now-retired dentist was found

using dirty tools ...

See all stories on this topic »

New Hepatitis C Data from Boehringer Ingelheim HCV Portfolio to Be Presented ...

Montreal Gazette

New data from the Boehringer Ingelheim hepatitis C virus (HCV) portfolio will be

presented in oral scientific sessions at the International Liver Congress TM

2011, the 46th Annual Meeting of the European Association for the Study of the

Liver (EASL), ...

See all stories on this topic »

Biolex to present final phase II B results of Hepatitis C drug Locteron at ...

pharmabiz.com

Biolex Therapeutics, Inc. announced that final results from its select-2 phase

II b trial of Locteron for the treatment of Hepatitis C has been accepted for

two presentations on March 31, 2011 at the 46th Annual Meeting of the European

Association for ...

See all stories on this topic »